The perils of Alzheimer's drug development

Curr Alzheimer Res. 2009 Feb;6(1):77-8. doi: 10.2174/156720509787313871.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Animals
  • Biomedical Research / methods
  • Biomedical Research / standards
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / standards*
  • Data Interpretation, Statistical
  • Dose-Response Relationship, Drug
  • Drug Evaluation / methods
  • Drug Evaluation / standards*
  • Drug Industry / methods
  • Drug Industry / standards
  • Humans
  • Observer Variation
  • Physostigmine / administration & dosage
  • Physostigmine / adverse effects
  • Physostigmine / analogs & derivatives
  • Selection Bias

Substances

  • Physostigmine
  • phenserine